John R. Murren, MD

Articles

Camptothecin and Taxane Regimens for Small-Cell Lung Cancer

Myron S. Kwong, MD;Eric Bleickardt, MD;John R. Murren, MD

September 2nd 2002

For more than 2 decades, combination chemotherapy has been the standard treatment for patients with small-cell lung cancer. Despite high initial response rates in both extensive- and limited-stage disease, long-term survival

Rationale for Non-Platinum Chemotherapy in Advanced NSCLC

John R. Murren, MD

July 1st 2001

During the past decade, five new cytotoxic drugs have beenintroduced that are active against non-small-cell lung cancer (NSCLC).

Rationale and Dose-Finding Studies of the Combination of Irinotecan and a Taxane on a Weekly Schedule

John R. Murren, MD;Kathleen Blum, RN;Randy Rich, MD

January 1st 2001

Cisplatin (Platinol)-based chemotherapy has been the standard systemic therapy for both non-small-cell and small-cell lung cancer for the past 2 decades, though the efficacy and benefit remain modest. Recently, several novel